Key Takeaways
- • Soufflé Therapeutics closed an oversubscribed $135 million Series B financing led by Juvia Group, according to the company's announcement, to advance its lead programs into clinical development.
- • The round included TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, Balyasny Asset Management and a leading sovereign wealth fund, alongside existing investors such as Amgen Ventures, ARCH Venture Partners, Bessemer Venture Partners and Temasek.
- • Proceeds will fund first clinical studies in facioscapulohumeral muscular dystrophy (FSHD), heart failure and muscle and metabolic disorders, with additional preclinical programs advancing in parallel.
- • The company's REMEDY (Receptor Mediated Delivery) platform aims to deliver oligonucleotide therapies to cell types outside the liver by targeting internalizing receptors with proprietary binders.
- • Boston-based Soufflé, led by CEO Amir Nashat, is positioning its FSHD program as a candidate for a disease with no currently approved disease-modifying therapies.
Summary
Soufflé Therapeutics has closed an oversubscribed $135 million Series B financing to advance its lead programs into clinical development and expand its pipeline of cell-specific oligonucleotide therapies, according to the company's announcement. The round was led by Juvia Group and included TCG Crossover Management, BB Biotech, Fidelity Management & Research Company, Balyasny Asset Management and a leading sovereign wealth fund. Existing investors Amgen Ventures, ARCH Venture Partners, Bessemer Venture Partners, Breyer Capital, The Invus Group, Janus Henderson, Leaps by Bayer, Polaris Partners, Safar Partners, TAS Partners, Temasek and Vida Ventures also participated.
The Boston-based company, led by CEO Amir Nashat, is developing an RNA therapeutics platform built on its proprietary REMEDY (Receptor Mediated Delivery) product engine. The technology is designed to enable cell-specific delivery of oligonucleotide therapies outside the liver by identifying internalizing receptors and generating proprietary binders, such as monoclonal antibodies and other ligands.
Proceeds will support the company's first clinical studies in facioscapulohumeral muscular dystrophy, heart failure, and muscle and metabolic disorders, while additional programs remain in preclinical development. The most advanced program targets striated muscle for FSHD, a disease for which the company notes there are currently no approved disease-modifying therapies. A second program targets the phospholamban (PLN) gene in cardiomyocytes for heart failure with reduced ejection fraction. The third lead program is directed at an undisclosed target involving muscle and metabolic disorders.
In a statement, Nashat said the investor backing supports the belief that the REMEDY platform can affect patients' lives. Stefan Vitorovic, co-founder and managing director of Juvia Group, said cell-selective delivery could change what medicines can achieve across many diseases. Chen Yu, managing partner at TCGX, said the firm was drawn to Soufflé's lead programs, which it described as already making meaningful progress in FSHD and heart failure, two diseases with very limited treatment options.
The Boston-based company, led by CEO Amir Nashat, is developing an RNA therapeutics platform built on its proprietary REMEDY (Receptor Mediated Delivery) product engine. The technology is designed to enable cell-specific delivery of oligonucleotide therapies outside the liver by identifying internalizing receptors and generating proprietary binders, such as monoclonal antibodies and other ligands.
Proceeds will support the company's first clinical studies in facioscapulohumeral muscular dystrophy, heart failure, and muscle and metabolic disorders, while additional programs remain in preclinical development. The most advanced program targets striated muscle for FSHD, a disease for which the company notes there are currently no approved disease-modifying therapies. A second program targets the phospholamban (PLN) gene in cardiomyocytes for heart failure with reduced ejection fraction. The third lead program is directed at an undisclosed target involving muscle and metabolic disorders.
In a statement, Nashat said the investor backing supports the belief that the REMEDY platform can affect patients' lives. Stefan Vitorovic, co-founder and managing director of Juvia Group, said cell-selective delivery could change what medicines can achieve across many diseases. Chen Yu, managing partner at TCGX, said the firm was drawn to Soufflé's lead programs, which it described as already making meaningful progress in FSHD and heart failure, two diseases with very limited treatment options.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.